Publications by authors named "Brigette N Corder"

Influenza A virus infection in swine impacts the agricultural industry in addition to its zoonotic potential. Here, we utilize epigraph, a computational algorithm, to design a universal swine H3 influenza vaccine. The epigraph hemagglutinin proteins are delivered using an Adenovirus type 5 vector and are compared to a wild type hemagglutinin and the commercial inactivated vaccine, FluSure.

View Article and Find Full Text PDF
Article Synopsis
  • - Oncolytic adenoviruses, particularly Ad type 5 (Ad5), have potential in cancer treatment, but face issues like high neutralizing antibodies and limited receptor expression in tumors, necessitating alternative options.
  • - The study examined four alternative adenoviral types (Ad26, 28, 45, and 48) for their ability to kill cancer cells and deliver a human sodium iodide symporter protein for targeted therapy, finding that species D Ads had the best results in specific cancer cell lines.
  • - Results indicated that species D Ads showed effective gene expression and cytotoxicity, especially in breast cancer cells, and have advantages over Ad5 due to lower pre-existing antibodies in the population and reduced toxicity,
View Article and Find Full Text PDF

On average, there are 3-5 million severe cases of influenza virus infections globally each year. Seasonal influenza vaccines provide limited protection against divergent influenza strains. Therefore, the development of a universal influenza vaccine is a top priority for the NIH.

View Article and Find Full Text PDF

The development of a safe and efficacious Zika virus (ZIKV) vaccine remains a global health priority. In our previous work, we developed an Adenovirus vectored ZIKV vaccine using a low-seroprevalent human Adenovirus type 4 (Ad4-prM-E) and compared it to an Ad5 vector (Ad5-prM-E). We found that vaccination with Ad4-prM-E leads to the development of a strong anti-ZIKV T-cell response without eliciting significant anti-ZIKV antibodies, while vaccination with Ad5-prM-E leads to the development of both anti-ZIKV antibody and T-cell responses in C57BL/6 mice.

View Article and Find Full Text PDF

Annually, influenza A virus (IAV) infects ~5-10% of adults and 20-30% of children worldwide. The primary resource to protect against infection is by vaccination. However, vaccination only induces strain-specific and transient immunity.

View Article and Find Full Text PDF

Adenovirus type 7 (Ad7) infection is associated with acute respiratory disease (ARD), especially in military recruits living in close quarters. Recently, several outbreaks of Ad7 infections have occurred in civilian populations, with some cases leading to death. However, the current Ad7 vaccine is licensed for use only in military recruits because it utilizes an orally delivered wild type virus which is shed in the stool for 28 days after immunization.

View Article and Find Full Text PDF

Zika virus (ZIKV) is a major public health concern due to the risk of congenital Zika syndrome in developing fetuses and Guillain-Barre syndrome in adults. Currently, there are no approved vaccines available to protect against infection. Adenoviruses are safe and highly immunogenic vaccine vectors capable of inducing lasting humoral and cellular immune responses.

View Article and Find Full Text PDF